Literature DB >> 9759865

Role of nuclear factor-kappa B and mitogen-activated protein kinase signaling pathways in IL-1 beta-mediated induction of alpha-PDGF receptor expression in rat pulmonary myofibroblasts.

P M Lindroos1, A B Rice, Y Z Wang, J C Bonner.   

Abstract

Induction of the alpha-platelet-derived growth factor receptor (PDGF-Ralpha) by IL-1beta in lung myofibroblasts enhances mitogenic and chemotactic responses to PDGF, and this could be a mechanism of myofibroblast hyperplasia during lung fibrogenesis. Since the regulation of many genes by IL-1beta involves activation of NF-kappaB and mitogen-activated protein (MAP) kinases, we examined these signaling pathways in the control of PDGF-Ralpha expression by IL-1beta in cultured rat lung myofibroblasts. Treatment of cells with pyrrolidine dithiocarbamate (PDTC), an antioxidant that inhibits NF-kappaB activation, completely blocked PDGF-Ralpha up-regulation by IL-1beta as assayed by [125I]PDGF-AA binding and PDGF-Ralpha mRNA expression, suggesting a role for NF-kappaB. However, while IL-1beta and TNF-alpha both induced nuclear binding of the Rel proteins p50 and p65 to an NF-kappaB consensus oligonucleotide in gel shift assays and caused transient degradation of inhibitor of NF-kappaB-alpha (IkappaB-alpha) in the cytoplasm of myofibroblasts, only IL-1beta upregulated PDGF-Ralpha. These results suggest that NF-kappaB activation alone is not sufficient for up-regulation of PDGF-Ralpha. An investigation of MAP kinase signaling pathways revealed that IL-1beta or PDTC activated extracellular signal-regulated kinase-2 (ERK-2) and c-jun NH2 terminal kinase-1 (JNK-1) phosphorylation of PHAS-1 and c-Jun substrates, respectively. Pretreatment of cells with the MAP kinase kinase-1 (MEK1) inhibitor PD 98059 blocked IL-1beta-induced activation of ERK-2 by more than 90% but enhanced IL-1beta-stimulated induction of PDGF-Ralpha expression fourfold. Taken together, these data suggest that IL-1beta activates both positive and negative signaling pathways that control the expression of PDGF-Ralpha. IL-1beta appears to mediate its negative effects on PDGF-Ralpha expression via MAP kinase activation, while the factor(s) that mediate induction of PDGF-Ralpha remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759865

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.

Authors:  Xu-Feng Zhang; Xinping Tan; Gang Zeng; Amalea Misse; Sucha Singh; Youngsoo Kim; James E Klaunig; Satdarshan P S Monga
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-kappaB signaling pathways.

Authors:  E D Chan; K R Morris; J T Belisle; P Hill; L K Remigio; P J Brennan; D W Riches
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 3.  PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer.

Authors:  Alexander Kikuchi; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2015

4.  NF-kappaB is involved in regulation of CD40 ligand expression on Mycobacterium bovis bacillus Calmette-Guérin-activated human T cells.

Authors:  Patricia Méndez-Samperio; Hilda Ayala; Abraham Vázquez
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

5.  Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy.

Authors:  Sudhiranjan Gupta; Nicole H Purcell; Anning Lin; Subha Sen
Journal:  J Cell Biol       Date:  2002-12-16       Impact factor: 10.539

6.  Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways.

Authors:  Long-Fei Sun; Dong-Qing An; Gu-Lijiamali Niyazi; Wen-Hui Ma; Zheng-Wei Xu; Yang Xie
Journal:  Mol Med Rep       Date:  2017-11-15       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.